Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273354 | 0.93 | ADAM17 (0.47) | ADAM17MMP1MMP3MMP9CTSS | |
| SCHEMBL4269899 | 0.86 | GRN (0.41) | ADAM17MMP1MMP3MMP9TAS1R3 | |
| SCHEMBL4633819 | 0.82 | TAS1R3 (0.39) | ADAM17MMP1MMP3MMP9ALDH1A1 | |
| SCHEMBL1810431 | 0.79 | ANPEP (0.45) | MMP1MMP3CTSSCTSKTAS1R3 | |
| SCHEMBL1812174 | 0.79 | ELANE (0.45) | CTSSCTSK | |
| SCHEMBL10003821 | 0.78 | SMN1; SMN2 (0.40) | ADAM17MMP1MMP3MMP9ALDH1A1 | |
| SCHEMBL1810398 | 0.78 | CTSK (0.44) | CTSSCTSK | |
| SCHEMBL1809936 | 0.76 | CA1 (0.40) | ALDH1A1SMN1; SMN2CYP3A4TSHRMEN1 | |
| SCHEMBL3973573 | 0.76 | GAA (0.43) | ALDH1A1ANPEPTSHR | |
| SCHEMBL3973571 | 0.76 | GAA (0.43) | ALDH1A1ANPEPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928475-B1 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES | RIBOSCIENCE LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-7608599-B2 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | ADAM17 4718/4885MMP1 4289/4885MMP3 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.